Literature DB >> 30339496

Genetic deletion of the alamandine receptor MRGD leads to dilated cardiomyopathy in mice.

Aline Cristina Oliveira1,2, Marcos Barrouin Melo1,2, Daisy Motta-Santos1,2, A Augusto Peluso1,2, Fernando Souza-Neto1,2, Rafaela F da Silva1,2, Jonathas F Q Almeida1,2, Giovanni Canta1,2, Adelina M Reis1,2, Gleisy Goncalves1,2, Gabriela Cerri1,2, Danielle Coutinho1,2, Itamar Couto Guedes de Jesus1,2, Silvia Guatimosim1,2, Natalia D Linhares3, Natalia Alenina4,5, Michael Bader4,5,6,7, Maria José Campagnole-Santos1,2, Robson A Souza Santos1,2.   

Abstract

We have recently described a new peptide of the renin-angiotensin system, alamandine, a derivative of angiotensin-(1-7). Mas-related G protein-coupled receptor member D (MrgD) was identified as its receptor. Although similar cardioprotective effects of alamandine to those of angiotensin-(1-7) have been described, the significance of this peptide in heart function is still elusive. We aimed to evaluate the functional role of the alamandine receptor MrgD in the heart using MrgD-deficient mice. MrgD was localized in cardiomyocytes by immunofluorescence using confocal microscopy. High-resolution echocardiography was performed in wild-type and MrgD-deficient mice (2 and 12 wk old) under isoflurane anesthesia. Standard B-mode images were obtained in the right and left parasternal long and short axes for morphological and functional assessment and evaluation of cardiac deformation. Additional heart function evaluation was performed using Langendorff isolated heart preparations and inotropic measurements of isolated cardiomyocytes. Immunofluorescence indicated that the MrgD receptor is expressed in cardiomyocytes, mainly in the membrane and perinuclear and nuclear regions. Echocardiography showed left ventricular remodeling and severe dysfunction in MrgD-deficient mice. Strikingly, MrgD-deficient mice presented a pronounced dilated cardiomyopathy with a marked decrease in systolic function. Echocardiographic changes were supported by the data obtained in isolated hearts and inotropic measurements in cardiomyocytes. Our data add new evidence for a major role for alamandine/MrgD in the heart. Furthermore, our results indicate that we have identified a new gene implicated in dilated cardiomyopathy, unveiling a new target for translational approaches aimed to treat heart diseases. NEW & NOTEWORTHY The renin-angiotensin system is a key target for cardiovascular therapy. We have recently identified a new vasodepressor/cardioprotective angiotensin, alamandine. Here, we unmasked a key role for its receptor, Mas-related G protein-coupled receptor member D (MrgD), in heart function. The severe dilated cardiomyopathy observed in MrgD-deficient mice warrants clinical and preclinical studies to unveil its potential use in cardiovascular therapy.

Entities:  

Keywords:  Mas-related G protein-coupled receptor member D; alamandine; dilated cardiomyopathy

Mesh:

Substances:

Year:  2018        PMID: 30339496     DOI: 10.1152/ajpheart.00075.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  13 in total

Review 1.  How ACE inhibitors transformed the renin-angiotensin system.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

2.  Alamandine enhances cardiomyocyte contractility in hypertensive rats through a nitric oxide-dependent activation of CaMKII.

Authors:  Itamar Couto Guedes Jesus; Thássio Ricardo Ribeiro Mesquita; André Luís Lima Monteiro; Amanda Borges Parreira; Anderson Kenedy Santos; Elizeu Lucas Xavier Coelho; Mário Morais Silva; Lucas A C Souza; Maria José Campagnole-Santos; Robson Souza Santos; Silvia Guatimosim
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

3.  Expression and Function of Mas-Related G Protein-Coupled Receptor D and Its Ligand Alamandine in Retina.

Authors:  Ping Zhu; Amrisha Verma; Tuhina Prasad; Qiuhong Li
Journal:  Mol Neurobiol       Date:  2019-08-07       Impact factor: 5.590

4.  Structural insight into the activation mechanism of MrgD with heterotrimeric Gi-protein revealed by cryo-EM.

Authors:  Shota Suzuki; Momoko Iida; Yoko Hiroaki; Kotaro Tanaka; Akihiro Kawamoto; Takayuki Kato; Atsunori Oshima
Journal:  Commun Biol       Date:  2022-07-15

5.  Reshaping the Preterm Heart: Shifting Cardiac Renin-Angiotensin System Towards Cardioprotection in Rats Exposed to Neonatal High-Oxygen Stress.

Authors:  Mariane Bertagnolli; Daniela R Dartora; Pablo Lamata; Ernesto Zacur; Thuy-An Mai-Vo; Ying He; Léonie Beauchamp; Adam J Lewandowski; Anik Cloutier; Megan R Sutherland; Robson A S Santos; Anne Monique Nuyt
Journal:  Hypertension       Date:  2022-05-19       Impact factor: 9.897

Review 6.  Sex differences in the metabolic effects of the renin-angiotensin system.

Authors:  Melissa C White; Rebecca Fleeman; Amy C Arnold
Journal:  Biol Sex Differ       Date:  2019-07-01       Impact factor: 5.027

7.  Redd1 protects against post‑infarction cardiac dysfunction by targeting apoptosis and autophagy.

Authors:  Pianpian Huang; Jun Fu; Long Chen; Chenhui Ju; Kefei Wu; Hongxia Liu; Yun Liu; Benming Qi; Benling Qi; Lihua Liu
Journal:  Int J Mol Med       Date:  2019-10-04       Impact factor: 4.101

Review 8.  Counter-regulatory renin-angiotensin system in cardiovascular disease.

Authors:  Maria Paz Ocaranza; Jaime A Riquelme; Lorena García; Jorge E Jalil; Mario Chiong; Robson A S Santos; Sergio Lavandero
Journal:  Nat Rev Cardiol       Date:  2019-08-19       Impact factor: 32.419

Review 9.  Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.

Authors:  Joshua R Cook; John Ausiello
Journal:  Rev Endocr Metab Disord       Date:  2021-07-01       Impact factor: 9.306

Review 10.  The renin-angiotensin system: going beyond the classical paradigms.

Authors:  Robson Augusto Souza Santos; Gavin Y Oudit; Thiago Verano-Braga; Giovanni Canta; Ulrike Muscha Steckelings; Michael Bader
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.